Search Results

You are looking at 1 - 10 of 51 items for :

  • Refine by Access: All x
Clear All
Full access

George D. Demetri, Robert S. Benjamin, Charles D. Blanke, Jean-Yves Blay, Paolo Casali, Haesun Choi, Christopher L. Corless, Maria Debiec-Rychter, Ronald P. DeMatteo, David S. Ettinger, George A. Fisher, Christopher D. M. Fletcher, Alessandro Gronchi, Peter Hohenberger, Miranda Hughes, Heikki Joensuu, Ian Judson, Axel Le Cesne, Robert G. Maki, Michael Morse, Alberto S. Pappo, Peter W. T. Pisters, Chandrajit P. Raut, Peter Reichardt, Douglas S. Tyler, Annick D. Van den Abbeele, Margaret von Mehren, Jeffrey D. Wayne, and John Zalcberg

, treatment, and supportive care and to document care as practiced at its member institutions. The NCCN guidelines on soft tissue sarcoma include a subsection on treatment recommendations for gastrointestinal stromal tumors (GISTs). The standard of practice

Full access

George D. Demetri, Margaret von Mehren, Cristina R. Antonescu, Ronald P. DeMatteo, Kristen N. Ganjoo, Robert G. Maki, Peter W.T. Pisters, Chandrajit P. Raut, Richard F. Riedel, Scott Schuetze, Hema M. Sundar, Jonathan C. Trent, and Jeffrey D. Wayne

Background Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Neoplastic GIST cells seem to arise from a common precursor cell, which gives rise to the interstitial cells of Cajal in

Full access

M. Zach Koontz, Brendan M. Visser, and Pamela L. Kunz

epithelium. Immunohistochemical staining for CD117 and DOG1 was positive, supporting the diagnosis of gastrointestinal stromal tumor (GIST). Repeat CT was performed, which showed a 11.2 x 8.3 cm mass ( Figure 1A ) arising from duodenum, with compression of

Full access

Margaret von Mehren

Verweij J Von Oosterom A Blay J . Imatinib Mesylate is an active agent for GIST but does not yield responses in other soft tissue sarcomas that are unselected for a molecular target . Eur J Cancer 2003 ; 39 : 2006 – 2011 . 60 Chugh R Thomas

Full access

Khalid Mamlouk, Zach Crouch, Philina Lee, Clive Mendonca, Maria Gumina, and Brian Rubin

Background: In the United States, 3,000–4,000 cases of GIST occur each year. Approximately 80% of newly diagnosed GIST harbor mutations in KIT and up to 10% harbor mutations in PDGFRA, including an activation loop mutation at amino acid 842 that is

Full access

Joshua B. Brown, Reetesh K. Pai, Melissa A. Burgess, Jennifer Chennat, and Amer H. Zureikat

Gastrointestinal stromal tumors (GISTs) are a class of subepithelial mesenchymal neoplasms typically arising in the alimentary tract from the interstitial cells of Cajal, and represent 1% of primary gastrointestinal tract cancers. Up to 90% of

Full access

Andrew Wagner

gastrointestinal stromal tumours with high-dose imatinib: randomised trial . Lancet 2004 ; 364 : 1127 – 1134 . 48. Rankin C Mehren MV Blanke C . Dose effect of imatinib (IM) in patients (pts) with metastatic GIST—phase III Sarcoma Group Study S0033

Full access

Maha Alkhuziem, Adam M. Burgoyne, Paul T. Fanta, Chih-Min Tang, and Jason K. Sicklick

Gastrointestinal stromal tumor (GIST) research set the precedent for precision medicine in solid tumors by identifying oncogenic driver mutations in the KIT gene 1 and matching this target with a cognate compound (ie, STI-571; later named

Full access

James Perkins, Patrick Boland, Steven J. Cohen, Anthony J. Olszanski, Yan Zhou, Paul Engstrom, and Igor Astsaturov

for NET Describe the rationale for the use of imatinib in the treatment of patients with NET with activating KIT mutations Evaluate the data supporting the hypothesis that NET and GIST arise from a common precursor Neuroendocrine tumors (NET

Full access

Margaret von Mehren, John M. Kane III, Richard F. Riedel, Jason K. Sicklick, Seth M. Pollack, Mark Agulnik, Marilyn M. Bui, Janai Carr-Ascher, Edwin Choy, Mary Connelly, Sarah Dry, Kristen N. Ganjoo, Ricardo J. Gonzalez, Ashley Holder, Jade Homsi, Vicki Keedy, Ciara M. Kelly, Edward Kim, David Liebner, Martin McCarter, Sean V. McGarry, Nathan W. Mesko, Christian Meyer, Alberto S. Pappo, Amanda M. Parkes, Ivy A. Petersen, Matthew Poppe, Scott Schuetze, Jacob Shabason, Matthew B. Spraker, Melissa Zimel, Mary Anne Bergman, Hema Sundar, and Lisa E. Hang

Karyopharm® Therapeutics. This activity is supported through an Independent Medical Education grant from Merck & Co., Inc. Overview Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma (STS) of the gastrointestinal tract